Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors

Modern Pathology

Volumn 19, Issue 10, 2006, Pages 1344-1350

  Koo, Chuay Yeng ^a   Bay, Boon Huat ^a   Lui, Philip Chi Wai ^b   Tse, Gary Man Kit ^b   Tan, Puay Hoon ^a,c   Yip, George Wai Cheong ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Heparan sulfate; Immunohistochemistry; Phyllodes tumor grade; Tissue microarray

Indexed keywords

HEPARAN SULFATE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E4; PROTEIN BCL 2; PROTEIN P53; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CELL; BREAST TUMOR; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; EMBRYO DEVELOPMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PHYLLODES TUMOR; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; STROMAL CELLS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748857960     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800657     Document Type: Article

References (52)

1. Kolset SO, Prydz K, Pejler G. Intracellular proteoglycans. Biochem J 2004;379:217-227.
2. Kramer KL, Yost HJ. Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 2003;37:461-484.
3. Sanderson RD, Bernfield M. Molecular polymorphism of a cell surface proteoglycan: distinct structures on simple and stratified epithelia. Proc Natl Acad Sci USA 1988;85:9562-9566.
4. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002;71:435-471.
5. Sugahara K, Kitagawa H. Heparan and heparan sulfate biosynthesis. IUBMB Life 2002;54:163-175.
6. Jayson GC, Lyon M, Paraskeva C, et al. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 1998;273:51-57.
7. Alini M, Losa GA. Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res 1991;51:1443-1447.
8. Gowda DC, Bhavanandan VP, Davidson EA. Structures of O-linked oligosaccharides present in the proteoglycans secreted by human mammary epithelial cells. J Biol Chem 1986;261:4935-4939.
9. Koda JE, Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. Basal extracellular proteoglycan binds specifically to native type I collagen fibrils. J Biol Chem 1984;259:11763-11770.
10. Rapraeger A, Bernfield M. Cell surface proteoglycan of mammary epithelial cells. Protease releases a heparan sulfate-rich ectodomain from a putative membrane-anchored domain. J Biol Chem 1985;260:4103-4109.
11. Safaiyan F, Lindahl U, Salmivirta M. Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem 1998;252:576-582.
12. Beauvais DM, Rapraeger AC. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 2003;286:219-232.
13. Bernfield M, Sanderson RD. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Philos Trans R Soc Lond B Biol Sci 1990;327:171-186.
14. Mali M, Andtfolk H, Miettinen HM, et al. Suppression of tumor cell growth by syndecan-1 ectodomain. J Biol Chem 1994;269:27795-27798.
15. Stanley MJ, Stanley MW, Sanderson RD, et al. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999;112:377-383.
16. Ridgway PF, Jacklin RK, Ziprin P, et al. Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index. J Surg Res 2004;122: 83-88.
17. Fechner RE, Mills SE. Breast pathology: Benign proliferations, atypias and in situ carcinomas 1990, American Society of Clinical Pathologists: Chicago.
18. Moffat CJ, Pinder SE, Dixon AR, et al. Phyllodes tumors of the breast: a clinicopathological review of thirty-two cases. Histopathology 1995;27:205-218.
19. Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol 2005;123:529-540.
20. Feakins RM, Wells CA, Young KA, et al. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Hum Pathol 2000;31: 1214-1222.
21. Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, et al. Altered expression of p53 and its regulated proteins in phyllodes tumors of the breast. J Pathol 1999;189:169-175.
22. Moore T, Lee AH. Expression of CD34 and bcl-2 in phyllodes tumors, fibroadenomas and spindle cell lesions of the breast. Histopathology 2001;38:62-67.
23. van den BJ, Salmivirta K, Henttinen T, et al. Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem 2005;280:20516-20523.
24. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 2005;18:1527-1534.
25. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-299.
26. Fuxe K, Chadi G, Tinner B, et al. On the regional distribution of heparan sulfate proteoglycan immunoreactivity in the rat brain. Brain Res 1994;636: 131-138.
27. Oshiro M, Ono K, Suzuki Y, et al. Immunohistochemical localization of heparan sulfate proteoglycan in human gastrointestinal tract. Histochem Cell Biol 2001;115:373-380.
28. Yip GW, Ferretti P, Copp AJ. Heparan sulfate proteoglycans and spinal neurulation in the mouse embryo. Development 2002;129:2109-2119.
29. Leteux C, Chai W, Nagai K, et al. 10E4 antigen of Scrapie lesions contains an unusual nonsulfated heparan motif. J Biol Chem 2001;276:12539-12545.
30. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004;6: 109-118.
31. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000;257: 231-237.
32. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
33. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-7220.
34. Kocova L, Skalova A, Fakan F, et al. Phyllodes tumor of the breast: immunohistochemical study of 37 tumors using MIB1 antibody. Pathol Res Pract 1998;194: 97-104.
35. Umekita Y, Yoshida H. Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol Int 1999;49:807-810.
36. Pellegrini L. Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 2001;11:629-634.
37. Lin X, Buff EM, Perrimon N, et al. Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development 1999;126:3715-3723.
38. Hardingham TE, Fosang AJ. Proteoglycans: many forms and many functions. FASEB J 1992;6:861-870.
39. Fernig DG, Chen HL, Rahmoune H, et al. Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. Biochem Biophys Res Commun 2000;267:770-776.
40. Mundhenke C, Meyer K, Drew S, et al. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 2002;160:185-194.
41. Nurcombe V, Smart CE, Chipperfield H, et al. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 2000;275:30009-30018.
42. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331: 834-842.
43. Mohapatra S, Chu B, Zhao X, et al. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005;65:7717-7723.
44. Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 2002;29:246-257.
45. Tse GM, Putti TC, Kung FY, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 2002;15:734-740.
46. Shpitz B, Bomstein Y, Sternberg A, et al. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features. J Surg Oncol 2002;79: 86-92.
47. Krajewski S, Thor AD, Edgerton SM, et al. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997;3:199-208.
48. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29-40.
49. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-734.
50. Carvalho S, Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumors: overexpression without mutations? J Clin Pathol 2004;57:1075-1079.
51. Tse GM, Putti TC, Lui PC, et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 2004;17:827-831.
52. Kuijper A, de Vos RA, Lagendijk JH, et al. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors. Am J Clin Pathol 2005;123:690-698.